Skip to main content
. 2019 Jan 15;234(8):14377–14388. doi: 10.1002/jcp.28139

Table 2.

Analysis of Gene Expression of Participant Populations

A Controls vs ED head trauma patients
Gene ΔCT±SD controls ΔCT±SD EDPT p value ΔCT FC±SD EDPT
ABCA1 9·51 ± 3·54 7·99 ± 1·80 0·0239 5·27 ± 6·73
AGER 8·60 ± 4·02 5·92 ± 2·95 0·0203 20·5 ± 32·75
APLP2 7·36 ± 3·24 5·33 ± 2·34 0·0008 17·20 ± 26·99
CDC2 9·62 ± 3·11 11·48 ± 3·70 0·055 6·90 ± 18·48
CSNK1A1 6·25 ± 2·57 3·92 ± 2·01 0·0071 15·9 ± 15·2
CSNK1D 4·80 ± 2·03 3·33 ± 1·58 0·004 5·34 ± 5·6
CTSD 4·68 ± 3·53 2·95 ± 2·27 0·0354 8·06 ± 5·09
GSK3B 6·44 ± 2·74 3·91 ± 1·25 0·0027 6·89 ± 5·87
IL1B −0·28 ± 5·95 −1·63 ± 1·39 0·055 2·72 ± 2·35
LRPAP1 7·67 ± 2·53 6·27 ± 1·12 0·0102 3·77 ± 4·39
MAPT 8·15 ± 2·81 10·93 ± 3·93 0·0477 3·0 ± 7·15
PRKCB1 5·8 ± 3·24 3·27 ± 2·04 0·0049 10·599 ± 15·49
PSEN1 6·94 ± 2·66 6·15 ± 2·05 0·0259 5·1 ± 7·64
SOAT1 8·67 ± 4·59 7·31 ± 2·09 0·044 7·51 ± 14·87
SOD2 1·24 ± 4·43 −0·74 ± 1·30 0·027 4·29 ± 3·22
B Controls versus Concussion clinic patients
ACHE 10·84 ± 3·86 12·8 ± 2·4 0·054 3·57 ± 14·31
APPBP1 9·54 ± 3·57 11·62 ± 1·71 0·0141 0·42 ± 0·65
CAPNS2 2·80 ± 3·05 −0·32 ± 2·03 0·0002 19·30 ± 167
CASP6 7·90 ± 2·88 10·41 ± 3·5 0·0811 2·11 ± 3·41
CDC2 9·62 ± 3·11 12·42 ± 2·73 0·006 1·83 ± 5·88
CDK5R1 3·90 ± 3·55 −0·69 ± 1·78 0·009 42·25 ± 41·46
CHRM1 3·99 ± 3·13 0·44 ± 1·80 0·0011 23·7 ± 30·48
CHRM3 5·22 ± 4·54 2·63 ± 4·7 0·011 34·97 ± 38·18
CHRNA7 10·91 ± 4·11 12·87 ± 2·9 0·051 16·89 ± 67·59
CSNK1A1 6·25 ± 2·57 3·4 ± 1·10 0·0002 14·0 ± 9·25
CTSD 4·68 ± 3·53 2·8 ± 2·69 0·0195 8·59 ± 6·55
GJB1 3·74 ± 3·44 −0·23 ± 1·74 0·0002 22·03 ± 18·3
GRIN2A 10·93 ± 3·79 13·05 ± 2·3 0·051 2·4 ± 9·8
SLC18A3 4·18 ± 4·97 1·71 ± 3·36 0·0153 15·71 ± 15·92
C Concussion clinic patients compared with ED head trauma patients
Gene ΔCT±SD CCPT FC±SD CCPT ΔCT±SD EDPT FC±SD EDPT EDPT vs CCPT p value
AGER 8·32 ± 3·37 5·65 ± 7·7 5·92 ± 2·95 20·17 ± 32·9 0·0243
APH1B 8·79 ± 2·8 1·2 ± 1·22 6·78 ± 2·07 3·23 ± 4·54 0·0398
APLP2 8·3 ± 3·46 5·5 ± 10·44 5·33 ± 2·34 17·0 ± 27·12 0·0159
BACE2 5·58 ± 1·81 3·97 ± 7·8 7·10 ± 1·95 0·65 ± 0·75 0·015
CAPNS2 −0·32 ± 2·03 19·30 ± 16·77 5·45 ± 4·31 1·36 ± 2·22 0·0001
CDK5R1 −0·69 ± 1·78 42·2 ± 41·46 2·21 ± 3·10 10·35 ± 15·76 0·003
CHRM1 0·44 ± 1·80 23·72 ± 30·48 5·42 ± 4·60 4·4 ± 7·5 0·0009
CHRM3 2·63 ± 4·7 34·9 ± 38·18 6·18 ± 4·03 6·09 ± 14·2 0·0044
CSNK1D 4·1 ± 0·90 2·2 ± 1·3 3·33 ± 1·58 5·2 ± 5·7 0·0398
GJB1 −0·23 ± 1·74 22·0 ± 18·33 4·57 ± 3·95 3·23 ± 6·36 0·0001
GSK3B 5·92 ± 2·4 2·94 ± 4·39 3·91 ± 1·25 6·82 ± 5·95 0·0034
IL1B −0·60 ± 1·36 1·4 ± 1·7 −1·63 ± 1·39 2·72 ± 2·35 0·0197
IL6 12·5 ± 2·71 1·66 ± 5·13 9·89 ± 2·62 4·37 ± 14·77 0·0143
MAPK1 5·48 ± 1·7 1·32 ± 0·95 4·62 ± 2·41 3·22 ± 2·57 0·0297
MME 6·64 ± 1·52 2·04 ± 1·86 5·58 ± 2·79 8·68 ± 16·2 0·0481
NCSTN 8·857 ± 1·95 0·84 ± 1·20 6·92 ± 1·62 2·17 ± 2·89 0·0023
PRKCB1 5·44 ± 2·31 1·98 ± 1·92 3·27 ± 2·04 10·46 ± 15·58 0·0012
PSEN1 7·72 ± 2·46 1·5 ± 1·09 6·15 ± 2·05 4·98 ± 7·77 0·0481
SLC18A3 1·71 ± 3·36 15·7 ± 15·9 6·04 ± 4·48 3·13 ± 5·87 0·002
SOAT1 8·82 ± 2·5 3·27 ± 4·9 7·31 ± 2·09 7·18 ± 15·03 0·0481
SOD2 0·94 ± 1·4 1·33 ± 0·87 −0·74 ± 1·30 4·29 ± 3·22 0·0018
ST6GAL1 10·69 ± 2·84 1·18 ± 1·85 8·62 ± 3·81 4·40 ± 7·08 0·0398
TNF 9·37 ± 4·13 2·4 ± 3·4 5·95 ± 3·23 7·76 ± 8·04 0·0114

Note. CT: cycle threshold; FC: fold change; SD: standard deviation.

(a) Comparison between controls (n = 23) and EDPT (n = 15), columns: gene, controls average ± SD delta CT, EDPT average ± SD delta CT, p value, and average ± SD FC.

(b) Comparison between controls (n = 23) and CCPT (n = 16), Columns: gene, controls average ± SD delta CT, CCPT average ± SD delta CT, p value, and average ± SD FC.

(c) Comparison of gene expression between CCPT and EDPT. Columns: gene, CCPT average ± SD delta CT, CCPT average ± SD FC, EDPT average ± SD delta CT, EDPT average ± SD FC, and the p value. CCPT: concussion clinic patients; EDPT: ED head trauma patients.